Format

Send to

Choose Destination
Haematologica. 2016 Oct;101(10):e427-e428.

Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system.

Author information

1
Smilow Cancer center at Yale New Haven Hospital, CT, USA Groupe Francophone des myélodysplasies, Hopital Saint Louis, Paris, France thomas.prebet@yale.edu.
2
Groupe Francophone des myélodysplasies, Hopital Saint Louis, Paris, France Service Hematologie Senior, Hopital Saint Louis, Paris, France.
3
Groupe Francophone des myélodysplasies, Hopital Saint Louis, Paris, France Service Hematologie 2, Institut Paoli-Calmettes, Marseille, France.

KEYWORDS:

acute myeloid leukemia; cytogenics and molecular genetics; hypomethylating agents; melodysplastic syndromes; stem cell transplantation

PMID:
27694503
PMCID:
PMC5046667
DOI:
10.3324/haematol.2016.150714
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center